Abvc biopharma provides vitargus® update on phase ii site initiation visit conducted at srinagarind hospital in thailand

Fremont, calif. , march 20, 2023 /prnewswire/ -- abvc biopharma, inc. (nasdaq: abvc), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology, today announced that vitargus® phase ii site initiation visit (siv) at srinagarind hospital, khon kaen university (th002) was successfully conducted on march 9-10, 2023.
ABVC Ratings Summary
ABVC Quant Ranking